Nilotinib Premix
Generic Name: nilotinib premix
Dosage form: POWDER. Active ingredients: NILOTINIB HYDROCHLORIDE MONOHYDRATE (1 kg/kg). Category: BULK INGREDIENT.
Overview
Dosage form: POWDER. Active ingredients: NILOTINIB HYDROCHLORIDE MONOHYDRATE (1 kg/kg). Category: BULK INGREDIENT.
Dosage
Available as powder.
Related Medications
Ranibizumab-nuna
ranibizumab-nuna
Vascular Endothelial Growth Factor Inhibitor [EPC]
11 DESCRIPTION BYOOVIZ (ranibizumab-nuna) is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Ranibizumab-nuna binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A). Ranibizumab-nuna, which lacks an Fc region, has a molecular weight of approximately 48 kilodaltons and is produced by an E. coli expression system in a nutrient medium containing the antibiotic tetracycline.
Human Albumin Microspheres And Perflutren
human albumin microspheres and perflutren
Contrast Agent for Ultrasound Imaging [EPC]
11 DESCRIPTION OPTISON (perflutren protein-type A microspheres) injectable suspension is an ultrasound contrast agent for intravenous use. Perflutren is chemically characterized as 1,1,1,2,2,3,3,3-perflutren with a molecular weight of 188, an empirical formula of C 3 F 8 , and the following structural formula: Each mL contains 5-8×10 8 protein-type A microspheres, 10 mg albumin human, 0.22 ± 0.11 mg perflutren, and the following inactive ingredients: 0.2 mg N-acetyltryptophan and 0.12 mg capryli
Paliperidone Palmitate
paliperidone palmitate
11 DESCRIPTION ERZOFRI (paliperidone palmitate) extended-release injectable suspension contains a racemic mixture of (+)- and (-)- paliperidone palmitate. Paliperidone palmitate, is an atypical antipsychotic belonging to the chemical class of benzisoxazole derivatives. The chemical name is (9 RS )-3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-4-oxo-6,7,8,9-tetrahydro-4 H -pyrido[1,2- a ]pyrimadin-9-yl hexadecanoate.
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.